A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors
© 2023. The Author(s)..
Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination (HR) deficiency. However, many patients without apparent HR defects also respond well to PARP inhibitors/cisplatin. The biomarker responsible for this mechanism remains unclear. Here, we identified a set of ribosomal genes that predict response to PARP inhibitors/cisplatin in HR-proficient patients. PARP inhibitor/cisplatin selectively eliminates cells with high expression of the eight genes in the identified panel via DNA damage (ATM) signaling-induced pro-apoptotic ribosomal stress, which along with ATM signaling-induced pro-survival HR repair constitutes a new model to balance the cell fate in response to DNA damage. Therefore, the combined examination of the gene panel along with HR status would allow for more precise predictions of clinical response to PARP inhibitor/cisplatin. The gene panel as an independent biomarker was validated by multiple published clinical datasets, as well as by an ovarian cancer organoids library we established. More importantly, its predictive value was further verified in a cohort of PARP inhibitor-treated ovarian cancer patients with both RNA-seq and WGS data. Furthermore, we identified several marketed drugs capable of upregulating the expression of the genes in the panel without causing HR deficiency in PARP inhibitor/cisplatin-resistant cell lines. These drugs enhance PARP inhibitor/cisplatin sensitivity in both intrinsically resistant organoids and cell lines with acquired resistance. Together, our study identifies a marker gene panel for HR-proficient patients and reveals a broader application of PARP inhibitor/cisplatin in cancer therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Signal transduction and targeted therapy - 8(2023), 1 vom: 10. Mai, Seite 183 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Chao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cisplatin |
|---|
| Anmerkungen: |
Date Completed 11.05.2023 Date Revised 27.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41392-023-01401-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356638219 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356638219 | ||
| 003 | DE-627 | ||
| 005 | 20231226070903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41392-023-01401-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356638219 | ||
| 035 | |a (NLM)37160887 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Chao |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.05.2023 | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination (HR) deficiency. However, many patients without apparent HR defects also respond well to PARP inhibitors/cisplatin. The biomarker responsible for this mechanism remains unclear. Here, we identified a set of ribosomal genes that predict response to PARP inhibitors/cisplatin in HR-proficient patients. PARP inhibitor/cisplatin selectively eliminates cells with high expression of the eight genes in the identified panel via DNA damage (ATM) signaling-induced pro-apoptotic ribosomal stress, which along with ATM signaling-induced pro-survival HR repair constitutes a new model to balance the cell fate in response to DNA damage. Therefore, the combined examination of the gene panel along with HR status would allow for more precise predictions of clinical response to PARP inhibitor/cisplatin. The gene panel as an independent biomarker was validated by multiple published clinical datasets, as well as by an ovarian cancer organoids library we established. More importantly, its predictive value was further verified in a cohort of PARP inhibitor-treated ovarian cancer patients with both RNA-seq and WGS data. Furthermore, we identified several marketed drugs capable of upregulating the expression of the genes in the panel without causing HR deficiency in PARP inhibitor/cisplatin-resistant cell lines. These drugs enhance PARP inhibitor/cisplatin sensitivity in both intrinsically resistant organoids and cell lines with acquired resistance. Together, our study identifies a marker gene panel for HR-proficient patients and reveals a broader application of PARP inhibitor/cisplatin in cancer therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Guo, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zheming |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Xiao-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Chengyang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qiuxue |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Jiahong |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Qunxian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Shizhen |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Liewei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Huanyao |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Nowsheen, Somaira |e verfasserin |4 aut | |
| 700 | 1 | |a Kloeber, Jake |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Chunbo |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Zhongqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Shuzhong |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Liangqing |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Lingying |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Xiaodong |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Qinglei |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Zhenkun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jin-San |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Signal transduction and targeted therapy |d 2016 |g 8(2023), 1 vom: 10. Mai, Seite 183 |w (DE-627)NLM257871861 |x 2059-3635 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:1 |g day:10 |g month:05 |g pages:183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41392-023-01401-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 1 |b 10 |c 05 |h 183 | ||